Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Equity Average (2019 - 2025)

Bioadaptives' Equity Average history spans 7 years, with the latest figure at -$1.3 million for Q3 2025.

  • For Q3 2025, Equity Average rose 26.59% year-over-year to -$1.3 million; the TTM value through Sep 2025 reached -$1.3 million, up 26.59%, while the annual FY2024 figure was -$1.6 million, 0.4% changed from the prior year.
  • Equity Average for Q3 2025 was -$1.3 million at Bioadaptives, up from -$1.4 million in the prior quarter.
  • Across five years, Equity Average topped out at -$1.2 million in Q4 2021 and bottomed at -$1.8 million in Q3 2024.
  • The 5-year median for Equity Average is -$1.4 million (2022), against an average of -$1.5 million.
  • The largest annual shift saw Equity Average tumbled 32.73% in 2021 before it increased 26.59% in 2025.
  • A 5-year view of Equity Average shows it stood at -$1.2 million in 2021, then plummeted by 32.19% to -$1.5 million in 2022, then increased by 8.36% to -$1.4 million in 2023, then dropped by 17.07% to -$1.6 million in 2024, then rose by 17.52% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Equity Average are -$1.3 million (Q3 2025), -$1.4 million (Q2 2025), and -$1.5 million (Q1 2025).